0R15 8432.9941 0.3331% 0R1E 7697.9961 -2.8767% 0M69 None None% 0R2V 220.12 9997.2477% 0QYR 1224.0 -0.6897% 0QYP 408.94 -0.0147% 0RUK 2670.0 -8.6242% 0RYA 1370.0 9.6% 0RIH 162.15 0.0% 0RIH 156.61 -3.4166% 0R1O 173.7 9825.7143% 0R1O None None% 0QFP 10659.5596 111.4992% 0M2Z 282.6 2.979% 0VSO 27.48 -22.8198% 0R1I None None% 0QZI 512.5 -2.1947% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 153.89 -0.7737%
Last update at 2024-08-30T20:22:00Z
Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
Thu 05 Sep 24, 03:21 PMPrediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
Thu 05 Sep 24, 01:10 PMBiotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
Wed 28 Aug 24, 02:11 PMRegeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
Tue 27 Aug 24, 03:12 PMAlnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
Fri 23 Aug 24, 02:22 PMBiotech Stock Roundup: CRL for REGN, GILD's Drug Approval, LQDA Down on News
Wed 21 Aug 24, 11:23 AMRegeneron (REGN) Gets CRL From FDA for Multiple Myeloma Drug
Wed 21 Aug 24, 11:19 AMRegeneron Provides Update on Biologics License Application for Linvoseltamab
Tue 20 Aug 24, 10:45 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 4858.80M | 9325.80M | 3810.40M | 2429.10M | 2553.50M |
| Minority interest | - | - | - | - | - |
| Net income | 4338.40M | 8075.30M | 3513.20M | 2115.80M | 2444.40M |
| Selling general administrative | 2115.90M | 1824.90M | 1346.00M | 1834.80M | 1556.20M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 10612.50M | 13634.20M | 7377.20M | 7081.20M | 6276.70M |
| Reconciled depreciation | 341.40M | 286.20M | 235.90M | 210.30M | 148.20M |
| Ebit | 4738.90M | 8946.80M | 3576.60M | 1999.50M | 2386.20M |
| Ebitda | 5173.30M | 9383.10M | 3867.30M | 2209.80M | 2534.40M |
| Depreciation and amortization | 434.40M | 436.30M | 290.70M | 210.30M | 148.20M |
| Non operating income net other | 179.30M | 436.30M | 290.70M | 249.50M | 47.30M |
| Operating income | 4738.90M | 8946.80M | 3576.60M | 2209.80M | 2534.40M |
| Other operating expenses | 7178.90M | 7124.90M | 4920.50M | 5653.60M | 4176.40M |
| Interest expense | 59.40M | 57.30M | 56.90M | 30.20M | 28.20M |
| Tax provision | 520.40M | 1250.50M | 297.20M | 313.30M | 109.10M |
| Interest income | 160.10M | - | - | 88.10M | 13.70M |
| Net interest income | 100.70M | -57.30000M | -56.90000M | -30.20000M | -28.20000M |
| Extraordinary items | - | - | - | - | 68.00M |
| Non recurring | 255.10M | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 520.40M | 1250.50M | 297.20M | 313.30M | 109.10M |
| Total revenue | 12172.90M | 16071.70M | 8497.10M | 7863.40M | 6710.80M |
| Total operating expenses | 5618.50M | 4687.40M | 3800.60M | 4871.40M | 3742.30M |
| Cost of revenue | 1560.40M | 2437.50M | 1119.90M | 782.20M | 434.10M |
| Total other income expense net | 119.90M | 379.00M | 233.80M | 219.30M | 19.10M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 4338.40M | 8075.30M | 3513.20M | 2115.80M | 2444.40M |
| Net income applicable to common shares | 4338.40M | 8075.30M | 3513.20M | 2115.80M | 2444.40M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 33080.20M | 29214.50M | 25434.80M | 17163.30M | 14805.20M |
| Intangible assets | 1038.60M | 915.50M | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | 386.60M | 933.00M | 332.40M | 1164.00M | 959.30M |
| Total liab | 7107.10M | 6550.50M | 6666.00M | 6138.00M | 3715.50M |
| Total stockholder equity | 25973.10M | 22664.00M | 18768.80M | 11025.30M | 11089.70M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 2357.90M | 1992.20M | 1725.30M | 122.40M | 781.10M |
| Common stock | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
| Capital stock | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M |
| Retained earnings | 27260.30M | 23306.70M | 18968.30M | 10893.00M | 7379.80M |
| Other liab | - | 707.80M | 515.30M | 635.50M | 889.00M |
| Good will | - | - | - | - | - |
| Other assets | - | 747.60M | 555.20M | 2770.00M | 913.30M |
| Cash | 2730.00M | 3105.90M | 2885.60M | 2193.70M | 1617.80M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 3423.40M | 3849.10M | 3451.00M | 2806.80M | 1790.90M |
| Current deferred revenue | 458.90M | 547.70M | 442.00M | 577.70M | 591.70M |
| Net debt | -27.10000M | -404.50000M | -185.90000M | 502.00M | -903.90000M |
| Short term debt | - | 720.00M | 719.70M | 1631.20M | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 2702.90M | 2701.40M | 2699.70M | 2695.70M | 713.90M |
| Other stockholder equity | -1206.40000M | -404.00000M | -173.40000M | 102.90M | 3688.70M |
| Property plant equipment | - | 3763.00M | 3482.20M | 3221.60M | 2890.40M |
| Total current assets | 19479.20M | 22064.70M | 20520.50M | 12753.90M | 10558.80M |
| Long term investments | 5396.50M | 6591.80M | 6838.00M | 3135.60M | 3256.80M |
| Net tangible assets | - | 21748.50M | 18768.80M | 11025.30M | 11089.70M |
| Short term investments | 8114.80M | 4636.40M | 2809.10M | 1393.30M | 1596.50M |
| Net receivables | 5667.30M | 5328.70M | 6036.50M | 4114.70M | 2672.20M |
| Long term debt | 1982.90M | 1981.40M | 1980.00M | 1978.50M | - |
| Inventory | 2580.50M | 2401.90M | 1951.30M | 1916.60M | 1415.50M |
| Accounts payable | 606.60M | 589.20M | 564.00M | 475.50M | 418.10M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -80.90000M | -238.80000M | -26.20000M | 29.30M | 21.10M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.10M | 0.10M | 0.10M | 0.10M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 23306.70M | 18968.30M | 10893.00M | 7379.80M |
| Treasury stock | - | - | -8260.90000M | -6613.30000M | -739.90000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 444.10M | -4658.80000M | 555.20M | 328.90M | 531.80M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 13601.00M | 7149.80M | 4914.30M | 4409.40M | 4246.40M |
| Capital lease obligations | 720.00M | 720.00M | 719.70M | 717.20M | 713.90M |
| Long term debt total | - | 1981.40M | 1980.00M | 1978.50M | 713.90M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -4976.60000M | -1937.40000M | -4832.80000M | 544.00M | -1598.20000M |
| Change to liabilities | - | -106.00000M | 745.90M | 267.00M | 738.50M |
| Total cashflows from investing activities | - | -3784.60000M | -5384.70000M | -70.60000M | -2027.80000M |
| Net borrowings | - | - | - | 1981.90M | 1981.90M |
| Total cash from financing activities | -1790.10000M | -1009.00000M | -1005.80000M | -1970.50000M | -252.10000M |
| Change to operating activities | - | -148.60000M | -240.70000M | 114.90M | -130.40000M |
| Net income | 3953.60M | 4338.40M | 8075.30M | 3513.20M | 2115.80M |
| Change in cash | -381.60000M | 221.30M | 690.80M | 577.00M | 150.10M |
| Begin period cash flow | 3119.40M | 2898.10M | 2207.30M | 1630.30M | 1480.20M |
| End period cash flow | 2737.80M | 3119.40M | 2898.10M | 2207.30M | 1630.30M |
| Total cash from operating activities | 4594.00M | 5014.90M | 7081.30M | 2618.10M | 2430.00M |
| Issuance of capital stock | 1217.10M | 1519.50M | 1672.30M | 2575.20M | 211.80M |
| Depreciation | 421.00M | 341.40M | 286.20M | 235.90M | 210.30M |
| Other cashflows from investing activities | - | -1257.10000M | - | - | -1598.20000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -271.70000M | -696.50000M | -494.30000M | -529.40000M | -335.50000M |
| Change to account receivables | -338.80000M | 707.80M | -1927.40000M | -1356.10000M | -473.10000M |
| Sale purchase of stock | -2935.60000M | -2528.50000M | -2678.10000M | -6527.60000M | -463.90000M |
| Other cashflows from financing activities | -700.60000M | -445.70000M | -1032.70000M | 3481.90M | -188.00000M |
| Change to netincome | - | 676.50M | -994.00000M | -895.10000M | 314.20M |
| Capital expenditures | 926.40M | 590.10M | 551.90M | 614.60M | 429.60M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 221.30M | 690.80M | 577.00M | 150.10M |
| Change in working capital | -94.10000M | -243.30000M | -1916.50000M | -1503.60000M | -200.50000M |
| Stock based compensation | 885.00M | 725.00M | 601.70M | 432.00M | 464.30M |
| Other non cash items | 266.30M | 599.80M | 181.70M | -135.00000M | -29.30000M |
| Free cash flow | 3667.60M | 4424.80M | 6529.40M | 2003.50M | 2000.40M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals Inc |
5.76 0.49% | 1184.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| NVO Novo Nordisk A/S |
1.64 1.19% | 139.16 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-0.0025 0.0018% | 138.74 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
2.54 0.51% | 495.89 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| CSLLY CSL Ltd |
-1.01 0.96% | 104.28 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
| Name | Title | Year Born |
|---|---|---|
| Dr. Leonard S. Schleifer M.D., Ph.D. | Founder, Pres, CEO & Director | 1953 |
| Dr. George D. Yancopoulos M.D., Ph.D. | Scientific Founder, Pres, Chief Scientific Officer & Director | 1960 |
| Mr. Robert E. Landry Jr. | Exec. VP of Fin. & CFO | 1964 |
| Mr. Joseph J. LaRosa | Exec. VP, Gen. Counsel & Sec. | 1959 |
| Dr. Andrew J. Murphy Ph.D. | Exec. VP of Research | 1959 |
| Mr. Daniel P. Van Plew | Exec. VP and GM of Industrial Operations & Product Supply | 1973 |
| Ms. Patrice Gilooly | Sr. VP of Quality Assurance & Operations | NA |
| Mr. Christopher R. Fenimore | Sr. VP, Head of Accounting & Controller | 1971 |
| Mr. Gerald Underwood | Sr. VP of Technical Operations | NA |
| Mr. Bob McCowan | Sr. VP of IT & Chief Information Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...